



# Proteomics International

LABORATORIES LTD

ASX/Media Release

12 September 2019

ASX code: PIQ

## PromarkerD test ready for launch in Europe

### Highlights

- **Proteomics International completes technology transfer of PromarkerD to clinical diagnostics partner Atturos**
- **Atturos to make the mass spectrometry version of PromarkerD available to licence partners in the European market**
- **The PromarkerD test system is the first test globally that is capable of predicting the onset of diabetic kidney disease**
- **Results of successful PromarkerD "cross-over" study to be presented in Precision Medicine and Clinical Proteomics section of the 18th Human Proteome Organization World Congress**
- **New markets for PromarkerD planned across Europe**

Medical technology company Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) announces that its partner, clinical diagnostics firm Atturos, has successfully transferred the PromarkerD technology to its laboratories in Ireland. Proteomics International's world-leading predictive diagnostic test for diabetic kidney disease, PromarkerD, will now be available as a mass spectrometry laboratory developed test (MS-LDT) to licence partners in the European market.

The completion of the technology transfer coincides with the publication this week of the PromarkerD clinical validation study results in the *Journal of Diabetes and its Complications* [ASX: 10 September 2019]. These results confirmed PromarkerD could correctly predict 86% of diabetes patients who went on to develop chronic kidney disease within four years.

Working closely with Proteomics International's scientists, Atturos have undertaken a stringent validation process of the PromarkerD method, and demonstrated data equivalence in 100 patient samples analysed in both laboratories. The results of this successful "cross-over" study will be presented in the Precision Medicine and Clinical Proteomics section of the 18th Human Proteome Organization (HUPO) World Congress to be held in Adelaide, 15-18 September 2019 (Abstract number 64584: PromarkerD as an immunoaffinity mass spectrometry assay for diabetic kidney disease).

Atturos Chief Scientific Officer, and President of the Human Proteome Organization (HUPO), Prof. Stephen Pennington said Atturos had applied the latest generation of analytical instrumentation (Agilent 6495 Triple Quadrupole LC/MS) to make the MS-LDT available, and are now in the process of establishing the PromarkerD method into an integrated and automated sample workflow that includes the Agilent Bravo Automated Liquid Handling Platform. "It is a significant milestone for our two pioneering companies to be expanding the use of mass spectrometry for new clinical diagnostic tests," he said.

Currently in Europe, diabetes affects 58 million people, a number that is expected to rise to 67 million people by 2045. An estimated one in three adults with diabetes already have chronic kidney disease, however, with early intervention it is possible to delay or prevent clinical symptoms of the disease.

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)

Proteomics International Managing Director Dr Richard Lipscombe said, “We are excited to be able to offer the test in Europe for the first time, and are working hard to give patients around the world the opportunity to know their diabetic kidney disease status. With dialysis treatment costing approximately €80,000 per year, PromarkerD has the potential to save patients and healthcare systems billions of dollars.”

Proteomics International is in discussions with tier-1 diagnostics and pharmaceutical companies, targeting the markets of Europe, Japan, India and the USA, to expand the global reach of PromarkerD.

ENDS

#### **About PromarkerD ([www.PromarkerD.com](http://www.PromarkerD.com))**

The PromarkerD test system assesses the risk of diabetic kidney disease in patients with type 2 diabetes. Chronic kidney disease is one of the major complications arising from diabetes and if unchecked can lead to dialysis or kidney transplant. PromarkerD is a simple blood test that uses a unique protein ‘fingerprint’ to provide an early detection of the onset of disease. In clinical studies published in leading journals PromarkerD correctly predicted 86% of otherwise healthy diabetics who went on to develop chronic kidney disease within four years. PromarkerD has received patent protection in multiple jurisdictions including Europe, China, Japan and the USA.

Further information is available through the PromarkerD web portal.

#### **About Atturos ([www.atturos.com](http://www.atturos.com))**

Atturos Ltd (Dublin, Ireland) is a privately funded clinical diagnostics company developing and commercialising advanced molecular diagnostics solutions to enable clinicians and patients make better healthcare decisions. A University College Dublin spin out company, Atturos was founded initially to commercialise the OCProDx test, a pioneering blood test that can determine whether diagnosed prostate cancer is confined to the prostate or has spread beyond it. The company is actively expanding its portfolio of advanced diagnostic solutions that address areas of significant clinical need.

#### **About Proteomics International Laboratories (PILL) ([www.proteomicsinternational.com](http://www.proteomicsinternational.com))**

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. It received the world’s first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the-art facilities located on Perth’s QEII Medical Campus. The Company’s business model uses its proprietary technology platform across three integrated areas of diagnostics, drug discovery and analytical services.

#### **For further information please contact:**

Dr Richard Lipscombe  
Managing Director  
Proteomics International Laboratories Ltd  
T: +61 8 9389 1992  
E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)

Dirk van Dissel  
[Corporate Advisor & Investor Relations]  
Adelaide Equity Partners  
T: +61 8 8232 8800  
E: [dvandissel@adelaideequity.com.au](mailto:dvandissel@adelaideequity.com.au)

Mike Feeney  
Chairman, Atturos  
T: + 353 87 830 9426  
E: [michael.feeney@atturos.com](mailto:michael.feeney@atturos.com)

Prof Stephen Pennington  
CSO, Atturos  
T: +353 87 137 0208  
E: [stephen.pennington@atturos.com](mailto:stephen.pennington@atturos.com)

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)